Findings

What do systematic reviews say?

1,139 questions · 1,173 findings · 89 reviews · Neuromuscular

Sort:Best matchNewestHighest certainty Download CSV

No studies found 302 · 25.7%GRADE not reported 119 · 10.1%Very low 267 · 22.8%Low 239 · 20.4%Moderate 177 · 15.1%High 69 · 5.9%

Methotrexate and azathioprine vs methotrexate (plus leucovorin)

Significant adverse events · people with inclusion body myositis

1 finding from 1 review

Treatment for inclusion body myositis 2015 · Cochrane Headline outcomes only
no estimate extracted
1 study · 11 participants
GRADE not reported

Oxandrolone vs placebo

Muscle strength · people with inclusion body myositis

2 findings from 1 review

Treatment for inclusion body myositis 2015 · Cochrane Headline outcomes only
no estimate extracted
1 study · 16 participants
GRADE not reported
Treatment for inclusion body myositis 2015 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Oxandrolone vs placebo

Change in muscle mass at 6 months (%) ‐ not measured · people with inclusion body myositis

1 finding from 1 review

Treatment for inclusion body myositis 2015 · Cochrane Headline outcomes only
no estimate extracted
1 study · 16 participants
GRADE not reported

Oxandrolone vs placebo

Change in handgrip strength at 6 months (%) ‐ not measured · people with inclusion body myositis

The review found no eligible studies for this question.

1 finding from 1 review

Treatment for inclusion body myositis 2015 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Oxandrolone vs placebo

Change in timed walk at 6 months (%) e.g. 10‐metre or 6‐minute walk test at 6 months ‐ not measured · people with inclusion body myositis

The review found no eligible studies for this question.

1 finding from 1 review

Treatment for inclusion body myositis 2015 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Oxandrolone vs placebo

Significant adverse events · people with inclusion body myositis

The review found no eligible studies for this question.

1 finding from 1 review

Treatment for inclusion body myositis 2015 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

IVIg vs placebo

Change in handgrip strength at 6 months (%) ‐ not measured · people with inclusion body myositis

The review found no eligible studies for this question.

1 finding from 1 review

Treatment for inclusion body myositis 2015 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

IVIg vs placebo

Change in timed walk at 6 months (%) e.g. 10‐metre or 6‐minute walk test at 6 months ‐ not measured · people with inclusion body myositis

The review found no eligible studies for this question.

1 finding from 1 review

Treatment for inclusion body myositis 2015 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

IVIg vs placebo

Significant adverse events · people with inclusion body myositis

1 finding from 1 review

Treatment for inclusion body myositis 2015 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 78 participants
GRADE not reported

Interferon beta‐1a vs placebo

Muscle strength · people with inclusion body myositis

2 findings from 1 review

Treatment for inclusion body myositis 2015 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 58 participants
Moderate
Treatment for inclusion body myositis 2015 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Interferon beta‐1a vs placebo

Change in muscle mass at 6 months (%) ‐ not measured · people with inclusion body myositis

1 finding from 1 review

Treatment for inclusion body myositis 2015 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 58 participants
Moderate

Mycophenolate mofetil vs placebo

Improvement in GNDS after 12 months1 · people with multifocal motor neuropathy

Mycophenolate mofetil showed no clear difference in improvement in GNDS after 12 months1 compared with placebo (moderate certainty).

1 finding from 1 review

Immunosuppressant and immunomodulatory treatments for multifocal motor neuropathy 2015 · Cochrane Headline outcomes only
RR 0.54 [0.06, 5.26]
1 study · 28 participants
Moderate

Mycophenolate mofetil vs placebo

Serious adverse events · people with multifocal motor neuropathy

1 finding from 1 review

Immunosuppressant and immunomodulatory treatments for multifocal motor neuropathy 2015 · Cochrane Headline outcomes only
no estimate extracted
1 study · 28 participants
Moderate

Plasma exchange vs sham exchange

Change in disability after 4 weeks disability grade change. Scale from: 0 to 10. · people with CIDP

1 finding from 1 review

Plasma exchange for chronic inflammatory demyelinating polyradiculoneuropathy 2015 · Cochrane Headline outcomes only
no estimate extracted
1 study · 36 participants
Moderate

Plasma exchange vs sham exchange

Change in impairment (NIS) after 4 weeks NIS score points. Scale from: 0 to 280; lower is better · people with CIDP

1 finding from 1 review

Plasma exchange for chronic inflammatory demyelinating polyradiculoneuropathy 2015 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 59 participants
High

Plasma exchange vs sham exchange

Change in mean compound muscle action potential amplitude after 4 weeks mA. Scale from: 0 to 10. · people with CIDP

1 finding from 1 review

Plasma exchange for chronic inflammatory demyelinating polyradiculoneuropathy 2015 · Cochrane Headline outcomes only
no estimate extracted
1 study · 30 participants
Moderate

Plasma exchange vs sham exchange

Serious adverse events ‐ not measured · people with CIDP

The review found no eligible studies for this question.

1 finding from 1 review

Plasma exchange for chronic inflammatory demyelinating polyradiculoneuropathy 2015 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Plasma exchange vs sham exchange

Only 1 trial. · people with CIDP

1 finding from 1 review

Plasma exchange for chronic inflammatory demyelinating polyradiculoneuropathy 2015 · Cochrane Headline outcomes only
no estimate extracted
1 study · 1 participants
GRADE not reported

Quinine vs placebo

Number of cramps over 2 weeks · patients with muscle cramps

1 finding from 1 review

Quinine for muscle cramps 2015 · Cochrane Headline outcomes only
no estimate extracted
13 studies · 952 participants
Low

Quinine vs a quinine‐vitamin E combination (Q‐Vel)

Cramp intensity (on 3‐point scale; 1 = mild; 2 = moderate; 3 = severe) · patients with muscle cramps

1 finding from 1 review

Quinine for muscle cramps 2015 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 510 participants
Low